Health Economics›Diffuse large B-cell lymphoma›Consolidation after salvage therapy

Consolidation after salvage therapy

Diffuse large B-cell lymphoma · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Busulfan, Fludarabine, Ibritumomab tiuxetan, then allo HSCT Variant #01 Partial	—	R 82 118	—	—	—	~1	~R 82 118 indirect	—
R-BEAM Variant #01 Partial	—	R 56 156	—	—	—	~1	~R 56 156 indirect	—
R-TBI/Cy Variant #01	—	R 52 985	—	—	—	~1	~R 52 985 indirect	—
Z-BEAM Variant #01 Partial	—	R 30 964	—	—	—	~1	~R 30 964 indirect	—
Fludarabine, Busulfan, Cyclophosphamide, then allo HSCT Variant #01 Partial	—	R 19 131	—	—	—	~1	~R 19 131 indirect	—
BeEAM Variant #01	—	R 18 312	—	—	—	~1	~R 18 312 indirect	—
CBV Variant #01 Partial	—	R 9 597	—	—	—	1	R 9 597 PFS proxy	2
LEED Variant #01	—	R 7 388	—	—	—	~1	~R 7 388 indirect	—
BEAC Variant #01 Partial	—	R 7 009	—	—	—	~1	~R 7 009 indirect	—
FEAM Variant #01 Partial	—	R 5 029	—	—	—	~1	~R 5 029 indirect	—
BEAM, then allo HSCT Variant #01 Partial	—	R 4 346	—	—	—	~1	~R 4 346 indirect	—
BEAM Variant #01 Partial	—	R 4 346	—	—	—	~1	~R 4 346 indirect	—
ESHAP Variant #01	—	R 3 886	21d	—	—	~8	~R 31 091 indirect	—
Cyclophosphamide and TBI Variant #01	—	R 1 176	—	—	~90.0 mo	~1	~R 1 176 PFS proxy · indirect	1

14 of 14 regimens shown